Exclusive Member Perks Await You

Kirsten R. Müller-Vahl is a specialist in neurology and psychiatry and senior physician at the Department of Psychiatry, Social Psychiatry and Psychotherapy at the Hannover Medical School (MHH) and leads there the "Tourette's Research Group" . She is the 1. chairwoman of the "Arbeitsgemeinschaft Cannabis als Medizin " and the "International Alliance for Cannabis as Medicine" (IACM) as well as member of the expert committee for narcotics of the Federal Opium Agency of the Federal Institute for Drugs and Medical Devices (BfArM) . She was an individual expert in the Committee on Health of the German Bundestag for the hearing on the draft law amending narcotics regulations on the marketability and prescribability of additional cannabis medicinal products. In 2017, she received the “IACM Award for Clinical Research for her special achievements regarding the re-introduction of cannabis and cannabinoids as medicine”. She is the principal investigator in numerous DFG, BMBF, EU and industry funded studies, including cannabis-based medicines and cannabinoid modulators, has more than 160 scientific articles and numerous book chapters and is co-editor of the standard work on cannabis as medicine: Müller-Vahl KR, Grotenhermen F (Hrg). Cannabis als Medizin, Berlin: MWV Medizinisch Wissenschaftliche Verlagsgesellschaft; 2020. ISBN: 978-3-95466-509-9. She is editor or member of the editorial board of the journals "Cannabis and Cannabinoid Research" and "Medical Cannabis and Cannabinoids".

Franjo Grotenhermen graduated in medicine and received his doctorate in Cologne. His fields of practice included internal medicine, surgery and naturopathy. He is head of the Centre for Cannabis Medicine in Steinheim (NRW) with a focus on therapy with cannabis and cannabinoids. Grotenhermen is Executive Director of the Arbeitsgemeinschaft Cannabis als Medizin e.V. (ACM) (since 1997), Executive Director of the International Association for Cannabinoid Medicines (IACM) (since 2000) and author of the IACM Information, which appears fortnightly in several languages on the IACM website. Grotenhermen is an employee of the Cologne-based nova Institute, co-owner of Endoxo GmbH (founded in 2019), a company that produces CBD and other hemp products. He is a lecturer at Dresden International University. He is Chief Medical Advisor of Telaleaf Health, an internet platform for telemedicine in the field of cannabis and cannabinoids. He is a member of the Scientific Advisory Board of the journals Cannabis and Cannabinoid Research, edited by Prof. Daniele Piomelli at Mary Ann Liebert Publishing, and of the Scientific Advisory Board of Medical Cannabis and Cannabinoids, edited by Prof. Rudolf Brenneisen at Karger Publishing. He is honorary president of the Union Francophone pour les Cannabinoïdes en Médecine (UFCM) as well as a member of the scientific advisory board of Portugal Medical Cannabis (PTMC). He received the following awards: Hanf-Preis 1999 of Cannabusiness, IACM 2011 Special Award, ICBC 2018 Lifetime Achievement Award, Robert Newman Memorial Award 2018 of Akzept e.V., Honorary Award GFS-Award 2021 of Gemeinnützige Forschungsvereinigung Saluplanta e.V..

Bonni Goldstein, MD is the Medical Director and Owner of Canna-Centers Wellness & Education, a California-based medical practice devoted to educating patients about the use of cannabis for serious and chronic medical conditions.  She completed her internship and residency at Children's Hospital Los Angeles, where she also served as chief resident.  She worked in the field of Pediatric Emergency Medicine in Los Angeles for 14 years. In 2008, she developed an interest in the science of medical cannabis after witnessing its beneficial effects in an ill friend. She has since evaluated thousands of patients for use of medical cannabis and is recognized as an expert in the clinical application of cannabis therapeutics. Dr. Goldstein has a special interest in treating children with intractable epilepsy, autism, cancer and other conditions. She has written two books on the clinical application of medicinal cannabis and published a number of articles pertaining to the use of cannabis for epilepsy and autism. Her current research focuses on pharmacometabolomics and the use of cannabis-responsive biomarkers to document cannabis treatment efficacy, guide clinical decision-making and improve outcomes in children with autism.

Dr. Ilya Reznik is a Board-certified specialist in Adult Forensic & Clinical Neuropsychiatry at MaReNa Diagnostic and Consulting Center, Israel. Dr. Ilya Reznik has a superior educational and professional record and documented contributions to the field of neuropsychiatric research, such as publications and other innovative activities. Dr. Reznik has published many original papers (including controlled trials), reviews, and case reports in leading peer-reviewed journals in clinical psychiatry and neuropsychopharmacology. His current main interest is in the field of the medicinal use of cannabis and cannabinoids, especially for various neuropsychiatric illnesses, such as Chronic Pain Syndrome, Fibromyalgia, Post-Traumatic Stress Disorder (PTSD), Epilepsy, Head/Brain Injury, OCD, ADHD, Gilles de la Tourette syndrome, Chronic Headache, Parkinson's and Alzheimer diseases, etc. During the last 14 years, Dr. Reznik gained extensive clinical & research experience working with cannabis and its products in NeuroPsychiatry and General & Complementary/Integrative Medicine. He coordinates the activity of the Israel National Forum for Medical Cannabis Research & Treatment and served as a professional advisor (and permanent participant and observer) to the Israeli Parliament (Knesset) Committee for Drugs and Alcohol Control and to Parliamentary Public Lobby for Medicinal Cannabis. Dr. Reznik is a renowned International Speaker on Cannabinoid Medicine issues. He is an Associate Member of The Canadian Consortium for the Investigation of Cannabinoids (CCIC) & of the International Cannabinoid Research Society (ICRS). In 2013 he was elected to the Board of Directors of, the International Association for Cannabinoid Medicines (IACM). In 2019 Dr. Ilya Reznik was appointed as an IACM Secretary for Partnership & Networking and promotes Educational and International activity within IACM.

Carola is the president of the Observatorio Español de Cannabis Medicinal and founder of the patient association dosemociones. She has been has been working tirelessly since 2014 for patients' rights, helping and advising on the properties of medical cannabis in Spain and Europe. Carola is also chair of the IACM Patient Council, an international coalition of patients' organizations that have gathered together to help give a voice to patients the world over and to work together in order to protect their rights and interests in the ever-developing world of medicinal cannabis.